---
layout: post
title: What is RNAi therapy?
categories: Infographics
date:   2017-11-15
description: Targeting the Untargetable
image: assets/images/RNAi/Preview.png
permalink: /RNAi
---

##Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases.


![My helpful RNAi infographic](assets/images/RNAi/171113_RNAi.png)

### References

##### Science Articles
1. [Bobbin M and Rossi J. (2016). RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? _Annu. Rev. Pharmacol. Toxicol._](https://www.ncbi.nlm.nih.gov/pubmed/?term=26738473)
2. [Chakraborty C. _et al._ (2017). Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine. _Molecular Therapy: Nucleic Acids_](https://www.ncbi.nlm.nih.gov/pubmed/?term=28918016)
3. [Dowdy S. (2017). Overcoming cellular barriers for RNA therapeutics. _Nature Biotechnology_](https://www.ncbi.nlm.nih.gov/pubmed/?term=28244992)
4. [Lam J. _et al._ (2015). siRNA Versus miRNA as Therapeutics for Gene Silencing. _Molecular Therapyâ€”Nucleic Acids Vol_](https://www.ncbi.nlm.nih.gov/pubmed/?term=26372022) 

##### Web
1. [Labiotech.eu, "RNA as a Therapy: Reviewing the Future Generation of Therapeutics"](https://labiotech.eu/rna-review-rnai-mrna/)
2. [Labiotech.eu, "Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?"](https://labiotech.eu/ultimate-review-how-could-mrna-overtake-all-other-biologicals-in-medicine/)

##### Clinical trial listed
* Cancer
  - miRNA mimic: MRX-34 (Mirna) - [Phase I (alted) - NCT01829971](https://clinicaltrials.gov/ct2/show/NCT01829971)
  - siRNA: siG12D LODER (Silenseed) - [Phase I/II completed - NCT01188785](https://clinicaltrials.gov/ct2/show/NCT01188785)
* Ophtalmologic:
  - miRNA: preclinical
  - siRNA: Bevasiranib (OPKO) - [Phase III abandoned - NCT00499590](https://clinicaltrials.gov/ct2/show/NCT00499590)
* Genetic:
  - miRNA: miRNA inhib: RG-012 (Regulus/Sanofi) - [Phase II - NCT02855268](https://clinicaltrials.gov/ct2/show/NCT02855268)
  - siRNA: Partisan (Alnylam) - [Phase III NCT01960348](https://clinicaltrials.gov/ct2/show/NCT01960348) & [NCT02510261](https://clinicaltrials.gov/ct2/show/NCT02510261)
* Infection: 
  - miRNA inhib: miravirsen (Santaris) - [Phase IIa - NCT01872936](https://clinicaltrials.gov/ct2/show/NCT01872936)
  - siRNA: ALN-RSV01 (Alnylam) - [Phase IIb completed - NCT01065935](https://clinicaltrials.gov/ct2/show/NCT01065935)
* Metab-cardio: 
  - miRNA inhib: RG-125 (Regulus/Sanofi) - [Phase I/IIa - NCT02826525](https://clinicaltrials.gov/ct2/show/NCT02826525)
  - siRNA: fitusiran (Alnylam/Sanofi) -  [Phase III - NCT02035605](https://clinicaltrials.gov/ct2/show/NCT02035605)
* Others:
  - miRNA mimics: MRG-201 (miRagen) - [Phase I NCT02603224](https://clinicaltrials.gov/ct2/show/NCT02603224)
  - siRNA: RX1-109 (RXi Pharma) - [Phase II - NCT02246465](https://clinicaltrials.gov/ct2/show/NCT02246465)